Summary
Pfizer Inc. announced a significant restructuring of its Research and Development (R&D) organization, strategically elevating Oncology to a standalone unit. This move is directly linked to Pfizer's planned future investments in oncology, including the proposed acquisition of Seagen Inc. The new structure aims to enhance focus and agility within its cancer drug development pipeline. As part of this reorganization, Dr. Mikael Dolsten, Chief Scientific Officer and President of Pfizer R&D, will oversee consolidated early and late-stage development, while Dr. Chris Boshoff transitions to Chief Oncology Research and Development Officer. Importantly, Dr. William Pao, the former Chief Development Officer, will be leaving the company effective August 15, 2023, due to the elimination of his role. His departure is classified as an involuntary termination without cause, triggering specific severance and equity acceleration provisions as outlined in his employment agreements and company plans.
Key Highlights
- 1Pfizer is restructuring its R&D organization, establishing Oncology as a distinct, stand-alone unit.
- 2This strategic shift is driven by planned future investments in Oncology, including the proposed acquisition of Seagen Inc.
- 3Dr. Chris Boshoff has been appointed Chief Oncology Research and Development Officer, EVP.
- 4Dr. Mikael Dolsten, CSO and President of R&D, will now lead the consolidated early and late-stage development efforts.
- 5Dr. William Pao, Chief Development Officer, EVP, is leaving Pfizer effective August 15, 2023, as his role is eliminated.
- 6Dr. Pao's departure is an involuntary termination without cause, entitling him to accelerated vesting of unvested awards, severance pay (one year's base salary and target bonus), and continued welfare benefits for two years.
- 7Severance is contingent on Dr. Pao executing a release of claims and adhering to restrictive covenants.